Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in glia

Rebecca C. Coll, Avril A. B. Robertson, Jae Jin Chae, Sarah Higgins, Raúl Muñoz-Planillo, Marco Inserra, Irina Vetter, Lara S. Dungan, Brian G. Monks, Andrea Stutz, Daniel E. Croker, Mark S. Butler, Moritz Haneklaus, Caroline E. Sutton, Gabriel Núñez, Eicke Latz, Daniel L. Kastner, Kingston H. G. Mills, Seth L. Masters, Kate Schroder, Matthew A. Cooper, Luke O'neill

Nature Medicine

Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in glia

Abstract

Discussion(0)

Related publications

Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis

Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis

Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes

The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases